Piper Jaffray Upgrades Genomic Health, Downgrades BD | GenomeWeb

NEW YORK (GenomeWeb News) - Investment bank Piper Jaffray today upgraded the stock of Genomic Health while downgrading its rating on Becton Dickinson.

It upgraded Genomic Health from "neutral" to "overweight."

The Redwood City, Calif.-based pharmacogenomic test maker yesterday announced the worldwide launch of its Oncotype Dx colon cancer test. The 12-gene expression test has been developed for assessing risk of disease recurrence in patients that have stage II colon cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.